학술논문
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7
Document Type
Article
Author
Source
In ESMO Open April 2021 6(2)
Subject
Language
ISSN
2059-7029